{"id":"ademetionine-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1088977","moleculeType":"Small molecule","molecularWeight":"398.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ademetionine (also known as SAMe) is the active form of methionine that serves as the primary methyl donor in the body. It participates in critical methylation reactions involved in neurotransmitter synthesis, phospholipid metabolism, and antioxidant defense. By restoring depleted SAM levels, it supports hepatocyte regeneration and improves liver function in cholestasis and hepatic disorders.","oneSentence":"Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:44.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cholestasis and intrahepatic cholestasis of pregnancy"},{"name":"Hepatic cirrhosis and liver dysfunction"},{"name":"Depression (secondary indication in some markets)"}]},"trialDetails":[{"nctId":"NCT07495995","phase":"PHASE2","title":"Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-04-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","enrollment":94},{"nctId":"NCT07367724","phase":"PHASE2","title":"Ademetionine in Obstructive Hypertrophic Cardiomyopathy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-01-01","conditions":"Obstructive Hypertrophic Cardiomyopathy (oHCM)","enrollment":44},{"nctId":"NCT06258525","phase":"PHASE2","title":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-03","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":30},{"nctId":"NCT06922669","phase":"NA","title":"Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Drug Induced Liver Injury","enrollment":232},{"nctId":"NCT04250259","phase":"PHASE2","title":"SAMe Trial for Patients With Alcoholic Cirrhosis","status":"RECRUITING","sponsor":"Indiana University","startDate":"2020-10-22","conditions":"Alcoholic Cirrhosis","enrollment":196},{"nctId":"NCT06026865","phase":"NA","title":"S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2023-08-01","conditions":"Primary Sclerosing Cholangitis (PSC)","enrollment":60},{"nctId":"NCT01899521","phase":"NA","title":"Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-05-01","conditions":"Alcoholism","enrollment":113},{"nctId":"NCT04832178","phase":"PHASE4","title":"Sumor as Adjuvant Therapy in Treatment-resistant Major Depression","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2021-06-01","conditions":"Major Depressive Disorder","enrollment":102},{"nctId":"NCT05340634","phase":"PHASE4","title":"Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.","status":"COMPLETED","sponsor":"Margan Biotech","startDate":"2020-04-20","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT02592434","phase":"PHASE3","title":"Efficacy Study Of Tofacitinib In Pediatric JIA Population","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-06-10","conditions":"Juvenile Idiopathic Arthritis","enrollment":225},{"nctId":"NCT03932474","phase":"NA","title":"EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY","status":"COMPLETED","sponsor":"Nutrilinea srl","startDate":"2018-09-17","conditions":"Depressive Symptoms","enrollment":90},{"nctId":"NCT00762268","phase":"NA","title":"A Trial of SAMe for Treatment-Resistant Bipolar Depression","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2008-09","conditions":"Bipolar Disorder, Depression, Bipolar Depression","enrollment":23},{"nctId":"NCT00694564","phase":"NA","title":"Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children","status":"COMPLETED","sponsor":"Huang, Jeannie, M.D.","startDate":"2007-06","conditions":"Abdominal Pain","enrollment":8},{"nctId":"NCT02557360","phase":"PHASE4","title":"Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2015-11","conditions":"Primary Biliary Cirrhosis","enrollment":24},{"nctId":"NCT01912196","phase":"PHASE2","title":"Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"MSI Methylation Sciences, Inc.","startDate":"2013-10","conditions":"Major Depressive Disorder (MDD)","enrollment":376},{"nctId":"NCT02200029","phase":"PHASE3","title":"Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption","status":"COMPLETED","sponsor":"Abbott","startDate":"2014-06","conditions":"Intrahepatic Cholestasis Associated With Alcoholic Liver Disease","enrollment":75},{"nctId":"NCT00528710","phase":"PHASE2","title":"Efficacy of S-Adenosylmethionine in Fibromyalgia","status":"COMPLETED","sponsor":"Deakin University","startDate":"2006-11","conditions":"Fibromyalgia Syndrome","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ademetionine tablet","genericName":"Ademetionine tablet","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ademetionine is a small molecule used in the treatment of various conditions, including depressive symptoms, major depressive disorder, and obstructive hypertrophic cardiomyopathy, among others. It is available in tablet form and has been studied in clinical trials, including a randomized, double-blind, placebo-controlled study to evaluate its efficacy in subjects with mild to moderate depression symptoms.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}